Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

multiple sclerosis/tyrosine

Link salvestatakse lõikelauale
10 tulemused
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 24 to 48 months.
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 24 to 48 months.

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 18 to 36 months.

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 18 to 36 months.

Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Test plan overview Project phase Phase II Indication: Complementary treatment of COVID 19 The purpose of the study: Examine the efficacy and tolerance of a chlorine dioxide based preparation Study design: Quasi-experimental clinical case study Number of patients expected: 20 patients. Main inclusion

Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This is a phase I clinical trial to evaluate the safety, tolerability, and maximum tolerated dose of DMF in patients with chronic lymphocytic leukemia. Patients with relapsed/refractory CLL not amenable to available therapies are eligible. This patient population is in need of novel therapies,

Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Masitinib is a selective tyrosine kinase inhibitor that is thought to exert a neuroprotective effect through its activity on mast cells and other non-neuronal cells of the central nervous system, with subsequent modulation of inflammatory and neurodegenerative processes. The objective of this study

The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The immune and clinical impacts of vitamin D in patients with chronic musculo-skeletal pain Background Vitamin D is a group of fat-soluble secosteroids, the two major physiologically relevant forms are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D without a subscript refers

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Chronic myeloid neoplasms (CMPN) consists of three main entities, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). These three disorders have many overlapping clinical features. The diseases are clonal stem cell disorders characterized by a chronic excess
Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge